Here we show that these similarities and differences among AML oncogenes can be reflected in their transforming effects on primary human CD34+ cells in vitro; and we combine this approach with early gene expression profiling to identify MDM2 as a possible mediator and drug target in AML1-ETO leukemogenesis. Here, RUNX1T1 is linked to acute myeloid leukemia.